BioScrip Inc (NASDAQ:BIOS) announced its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02), Briefing.com reports. The business had revenue of $198.70 million during the quarter, compared to analyst estimates of $202.91 million. During the same period in the previous year, the business earned ($0.12) EPS. BioScrip’s revenue for the quarter was down 11.5% on a year-over-year basis.

Shares of BioScrip (NASDAQ BIOS) traded up $0.16 during midday trading on Friday, hitting $2.07. 910,580 shares of the stock were exchanged, compared to its average volume of 961,951. The company has a debt-to-equity ratio of -7.49, a current ratio of 1.85 and a quick ratio of 1.57. BioScrip has a fifty-two week low of $0.98 and a fifty-two week high of $3.39.

A number of analysts recently issued reports on the company. ValuEngine upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and upped their target price for the company from $3.25 to $3.75 in a research report on Thursday, August 10th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $3.75.

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/bioscrip-inc-bios-issues-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

In other BioScrip news, Director Coliseum Capital Management, L sold 2,846,941 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $2.93, for a total value of $8,341,537.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael G. Bronfein sold 27,000 shares of BioScrip stock in a transaction on Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the sale, the director now directly owns 129,669 shares of the company’s stock, valued at $348,809.61. The disclosure for this sale can be found here. Insiders have sold a total of 3,760,419 shares of company stock valued at $11,144,519 in the last ninety days. 0.80% of the stock is currently owned by corporate insiders.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Earnings History for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc and related companies with MarketBeat.com's FREE daily email newsletter.